Related Experiment Video

Updated: Jun 5, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Presenting features and treatment outcome of acute promyelocytic leukemia arising after multiple sclerosis

Emanuele Ammatuna1, Pau Montesinos, Syed Khizer Hasan

  • 1Department of Biopathology, University Tor Vergata, Rome, Italy.

Haematologica
|January 4, 2011
PubMed

Insights

Multiple sclerosis patients developing acute promyelocytic leukemia (APL) showed good remission rates with all-trans retinoic acid and chemotherapy or arsenic trioxide. Further investigation of less toxic agents like arsenic trioxide is warranted.

Area of Science:

  • Hematology
  • Oncology
  • Neurology

Background:

  • Multiple sclerosis (MS) patients treated with mitoxantrone have a risk of developing acute promyelocytic leukemia (APL).
  • Understanding the clinical features and treatment outcomes in this specific patient cohort is crucial for improving management.

Purpose of the Study:

  • To report the clinical characteristics and treatment outcomes of 33 patients with multiple sclerosis who developed acute promyelocytic leukemia.
  • To evaluate the efficacy of different treatment regimens, including all-trans retinoic acid and arsenic trioxide.

Main Methods:

  • Retrospective analysis of 33 patients with MS and APL.
  • Review of treatment protocols including all-trans retinoic acid, chemotherapy, and arsenic trioxide.
  • Assessment of hematologic remission, relapse rates, and overall survival.

Main Results:

  • A median latency of 32 months was observed between mitoxantrone treatment and APL diagnosis.
  • The PML-RARA bcr1 iso-form was identified in 87% of cases.
  • 90% of patients achieved hematologic remission; 5-year cumulative incidence of relapse was 23% and overall survival was 68%.

Conclusions:

  • All-trans retinoic acid and chemotherapy or arsenic trioxide are effective in achieving remission for MS patients with APL.
  • Arsenic trioxide shows promise as a less toxic agent warranting further investigation in this context.
  • Long-term follow-up is essential to monitor for relapses and secondary malignancies.

More Related Videos

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...